3 Prévost-Blondel A, Roth E, Rosenthal FM, et al. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo[J]. J Immmunol, 2000, 164(7): 3645-3651.
6 Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer[J]. BJU Int, 2002, 89(6): 538-542.
[7]
7 Whitmore WF Jr. Natural history and staging of prostate cancer[J]. Urol Clin North Am, 1984, 11(2): 205-210.
[8]
8 Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Natl Cancer Inst, 1992, 84(17): 1875-1887.
12 Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients[J]. Anticancer Res, 2001, 21(2B): 1355-1358.
[13]
13 Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1 beta in patients with renal cell carcinoma[J]. Br J Cancer, 2002, 86(9): 1396-1400.
16 Durkan GC, Nutt JE, Marsh C, et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer[J]. Clin Cancer Res, 2003, 9(7): 2576-2582.
[17]
17 Sier CF, Casetta G, Veheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers[J]. Clin Cancer Res, 2000, 6(6): 2333-2340.